A Phase 3 interventional study of dalcetrapib and Placebo in Acute Coronary Syndrome, sponsored by DalCor Pharmaceuticals. Completed at 563 sites in 32 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2022-10-12.
Sponsored by DalCor Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.
Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 21st largest by enrollment of the 186 interventional ones that give a count, is one of 13 that started in 2016, is one of 40 in phase 3, and was the 164th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Shanghai CureGene Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–55 · Healthy volunteers
Columbia University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of South Florida · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 36 · Phase 3 41 · Phase 4 27
First in 2001; this study’s year is marked. 13 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6,147 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 150 across the 186 interventional studies, 500 across the 79 observational. Of the 214 that completed or were terminated, 97 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 265 have an industry lead sponsor. The 10 most frequent:
DalCor Pharmaceuticals is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
DalCor Pharmaceuticals has 2 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Acute Coronary Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05918861Phase 3DalCor PharmaceuticalsEffect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | 2027-08 |
| NCT06481943SB Technology, Inc.A Prospective Research Investigation of Ischemia Using MCG | 2026-12 |
| NCT05412927Angel Medical SystemsAngelMed Guardian® System PMA Post Approval Study | 2026-12 |
| NCT04496687SCAD AllianceInternational Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry | 2026-12-31 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 265 studies in Acute Coronary Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in the hospital and will continue following release from the hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (4-12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.
This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints.
Those who are likely to qualify will undergo Genotype Assay Testing to evaluate genetic determination or the presence of the AA genotype. The test is investigational and test procedures are Roche Molecular Diagnostics protocol ADCY9-COB-389.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(*) Varies by region
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received dalcetrapib 600 mg (two 300 mg tablets) orally once daily. dalcetrapib: Cholesterol Ester Transfer Protein inhibitor, 300 mg tablets
Drug: dalcetrapib
Participants received dalcetrapib placebo tablets matching dalcetrapib orally once daily. Placebo: dalcetrapib matching placebo tablets
Drug: Placebo
Cholesterol Ester Transfer Protein inhibitor
matching placebo tablets
Composite of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, and Non-Fatal Stroke
All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The primary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite endpoint, which included death from cardiovascular causes, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke, as positively adjudicated by the CEC.
Time frame: From randomization to the first occurrence of any component of the composite primary endpoint (median duration of follow-up was 39.9 months)
Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke, Hospitalization for ACS (With Electrocardiogram Abnormalities) or Unanticipated Coronary Revascularization
All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The primary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite endpoint, which included death from cardiovascular causes, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, hospitalization for acute coronary syndrome (with electrocardiogram abnormalities) or unanticipated coronary revascularization, as positively adjudicated by the CEC.
Time frame: From randomization to the first occurrence of any component of the composite secondary endpoint (median duration of follow-up was 39.9 months)
Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke or Hospitalization for New or Worsening Heart Failure
All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The secondary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite secondary endpoint, which included death from cardiovascular causes, cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for new or worsening heart failure, as positively adjudicated by the CEC.
Time frame: From randomization to the first occurrence of any component of the composite secondary endpoint (median duration of follow-up was 39.9 months)
Trial enrolment began in April 2016 and was completed in December 2018. A total of 45,005 patients with recent acute coronary syndrome were screened in order to identify participants meeting the single genetic criterion (AA genotype at rs1967309 in the ADCY9 gene) and other inclusion criteria and no exclusion criteria required for randomization.
| Milestone | Dalcetrapib | Placebo |
|---|---|---|
| Started | 3071 | 3076 |
| Took study medication | 3064 | 3064 |
| Completed | 2840 | 2833 |
| Not completed | 231 | 243 |
| Withdrew: Lost to follow-up | 27 | 24 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 24 | 39 |
| Withdrew: Death | 180 | 179 |
All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The primary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite endpoint, which included death from cardiovascular causes, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke, as positively adjudicated by the CEC.
| Participants | Placebo | Dalcetrapib |
|---|---|---|
| Composite of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, and Non-Fatal Stroke | 327 | 292 |
All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The primary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite endpoint, which included death from cardiovascular causes, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, hospitalization for acute coronary syndrome (with electrocardiogram abnormalities) or unanticipated coronary revascularization, as positively adjudicated by the CEC.
| Participants | Placebo | Dalcetrapib |
|---|---|---|
| Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke, Hospitalization for ACS (With Electrocardiogram Abnormalities) or Unanticipated Coronary Revascularization | 471 | 471 |
All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The secondary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite secondary endpoint, which included death from cardiovascular causes, cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for new or worsening heart failure, as positively adjudicated by the CEC.
| Participants | Placebo | Dalcetrapib |
|---|---|---|
| Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke or Hospitalization for New or Worsening Heart Failure | 346 | 321 |
Collected over From randomization through 14 days after end of study (median duration of follow-up was 39.9 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 180/3,076 (5.9%) | 923/3,076 (30%) | 818/3,076 (26.6%) |
| Dalcetrapib | 182/3,071 (5.9%) | 900/3,071 (29.3%) | 971/3,071 (31.6%) |
| Event | Placebo | Dalcetrapib |
|---|---|---|
| Chest painGeneral disorders | 79/3076 | 81/3071 |
| Angina pectorisCardiac disorders | 50/3076 | 52/3071 |
| Corona virus infectionInfections and infestations | 43/3076 | 45/3071 |
| Non-cardiac chest painGeneral disorders | 28/3076 | 41/3071 |
| PneumoniaInfections and infestations | 41/3076 | 39/3071 |
| Atrial fibrillationCardiac disorders | 36/3076 | 31/3071 |
| Coronary artery diseaseCardiac disorders | 23/3076 | 30/3071 |
| SyncopeNervous system disorders | 28/3076 | 24/3071 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 27/3076 | 23/3071 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 27/3076 | 10/3071 |
| Event | Placebo | Dalcetrapib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 186/3076 | 300/3071 |
| HypertensionVascular disorders | 266/3076 | 277/3071 |
| Chest painGeneral disorders | 239/3076 | 268/3071 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 155/3076 | 152/3071 |
| Age, Continuous(years) | Dalcetrapib | Placebo | Total |
|---|---|---|---|
| Mean | 62.19 ± 9.16 | 62.34 ± 9.25 | 62.26 ± 9.21 |
| Sex: Female, Male(Participants) | Dalcetrapib | Placebo | Total |
|---|---|---|---|
| Female | 723 | 672 | 1395 |
| Male | 2348 | 2404 | 4752 |
| Ethnicity (NIH/OMB)(Participants) | Dalcetrapib | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 469 | 469 | 938 |
| Not Hispanic or Latino | 2551 | 2550 | 5101 |
| Unknown or Not Reported | 51 | 57 | 108 |
| Race (NIH/OMB)(Participants) | Dalcetrapib | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 12 | 23 |
| Asian | 58 | 59 | 117 |
| Native Hawaiian or Other Pacific Islander | 15 | 15 | 30 |
| Black or African American | 130 | 123 | 253 |
| White | 2771 | 2798 | 5569 |
| More than one race | 85 | 68 | 153 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Dalcetrapib | Placebo | Total |
|---|---|---|---|
| United Arab Emirates | 9 | 7 | 16 |
| Argentina | 74 | 74 | 148 |
| Australia | 100 | 102 | 202 |
| Austria | 23 | 27 | 50 |
| Belgium | 22 | 17 | 39 |
| Bulgaria | 201 | 185 | 386 |
| Brazil | 218 | 213 | 431 |
| Canada | 209 | 228 | 437 |
| Switzerland | 21 | 15 | 36 |
| Chile | 44 | 50 | 94 |
| Czechia | 73 | 78 | 151 |
| Germany | 28 | 41 | 69 |
| Denmark | 66 | 71 | 137 |
| Spain | 84 | 104 | 188 |
| Finland | 9 | 11 | 20 |
| France | 49 | 50 | 99 |
| United Kingdom | 200 | 183 | 383 |
| Hungary | 82 | 101 | 183 |
| Israel | 198 | 175 | 373 |
| Italy | 69 | 54 | 123 |
| Netherlands | 129 | 147 | 276 |
| New Zealand | 75 | 74 | 149 |
| Poland | 166 | 169 | 335 |
| Puerto Rico | 10 | 4 | 14 |
| Romania | 92 | 87 | 179 |
| Russia | 215 | 240 | 455 |
| Slovakia | 21 | 27 | 48 |
| Sweden | 35 | 30 | 65 |
| Turkey | 31 | 26 | 57 |
| United States | 370 | 358 | 728 |
| South Africa | 121 | 101 | 222 |
| Portugal | 27 | 27 | 54 |
| Reproductive status if female(Participants) | Dalcetrapib | Placebo | Total |
|---|---|---|---|
| Childbearing potential with double contraceptive protection | 24 | 24 | 48 |
| Childbearing potential without double contraceptive potential | 1 | 1 | 2 |
| Postmenopausal | 602 | 584 | 1186 |
| Surgically sterilized | 92 | 60 | 152 |
| Other | 4 | 3 | 7 |
| Acute Coronary Syndrome (ACS) Index Event Details:(days) | Dalcetrapib | Placebo | Total |
|---|---|---|---|
| Time since ACS index event | 53.82 ± 18.09 | 54.01 ± 18.31 | 53.91 ± 18.20 |
| Hospitalization duration | 6.06 ± 4.33 | 6.22 ± 5.03 | 6.14 ± 4.69 |
| Acute Coronary Syndrome (ACS) Index Event Diagnosis(Participants) | Dalcetrapib | Placebo | Total |
|---|---|---|---|
| Spontaneous Myocardial Infarction (MI) | 2756 | 2742 | 5498 |
| Procedure-related Myocardial Infarction (MI) after Percutaneous Coronary Intervention (PCI) | 20 | 28 | 48 |
| Hospitalization for Acute Coronary Syndrome (Electrocardiogram abnormalities without biomarkers) | 295 | 306 | 601 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 563 sites across 32 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2016 to primary completion in Oct 2021, 66 months.
Results were first posted in Oct 2022, 1 year after primary completion.
Of 39 phase 3 interventional studies under Acute Coronary Syndrome, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 66 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dalcetrapib